PubMed

Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial.

Schwartz GG, Olsson AG, Szarek M, Sasiela WJ.

Diabetes Care. 2005 Oct;28(10):2508-13.PMID: 16186288 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.

JAMA. 2001 Apr 4;285(13):1711-8.PMID: 11277825 [PubMed - indexed for MEDLINE]Related articlesFree article

Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

Arca M.

Drugs. 2007;67 Suppl 1:43-54. Review.PMID: 17910520 [PubMed - indexed for MEDLINE]Related articles

Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.

Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T; MIRACL Study Investigators.

Circulation. 2002 Sep 24;106(13):1690-5.PMID: 12270864 [PubMed - indexed for MEDLINE]Related articlesFree article

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators.

Lancet. 2006 Sep 9;368(9539):919-28.PMID: 16962881 [PubMed - indexed for MEDLINE]Related articles

Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

Arca M, Gaspardone A.

Drugs. 2007;67 Suppl 1:29-42. Review.PMID: 17910519 [PubMed - indexed for MEDLINE]Related articles

Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).

Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, Ouyang P, Piotrowicz R, Schenck-Gustafsson K, Sellier P, Stein JH, Thompson PL, Tzivoni D.

Circulation. 2007 Feb 13;115(6):700-7. Epub 2007 Feb 5.PMID: 17283260 [PubMed - indexed for MEDLINE]Related articlesFree article

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.

JAMA. 2005 Nov 16;294(19):2437-45. Erratum in: JAMA. 2005 Dec 28;294(24):3092. PMID: 16287954 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.

Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.

Circulation. 2004 Jul 27;110(4):386-91. Epub 2004 Jul 19.PMID: 15262833 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study).

Olsson AG, Schwartz GG, Szarek M, Luo D, Jamieson MJ.

Am J Cardiol. 2007 Mar 1;99(5):632-5. Epub 2007 Jan 9.PMID: 17317362 [PubMed - indexed for MEDLINE]Related articles

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.

Diabetes Care. 2006 Jun;29(6):1220-6.PMID: 16731999 [PubMed - indexed for MEDLINE]Related articlesFree article

High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.

Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A.

Eur Heart J. 2005 May;26(9):890-6. Epub 2005 Mar 11.PMID: 15764620 [PubMed - indexed for MEDLINE]Related articlesFree article

Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.

Ray KK, Cannon CP.

Curr Opin Lipidol. 2004 Dec;15(6):637-43. Review.PMID: 15529022 [PubMed - indexed for MEDLINE]Related articles

A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.

Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, Califf R, Braunwald E.

Circulation. 2006 Mar 21;113(11):1406-14. Epub 2006 Mar 13.PMID: 16534008 [PubMed - indexed for MEDLINE]Related articlesFree article

Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.

O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E.

Circulation. 2006 Apr 11;113(14):1745-52. Epub 2006 Mar 14.PMID: 16537575 [PubMed - indexed for MEDLINE]Related articlesFree article

Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators.

N Engl J Med. 2005 Apr 7;352(14):1425-35. Epub 2005 Mar 8.PMID: 15755765 [PubMed - indexed for MEDLINE]Related articlesFree article

Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.

Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, Braunwald E.

J Am Coll Cardiol. 2008 Sep 9;52(11):914-20.PMID: 18772061 [PubMed - indexed for MEDLINE]Related articles

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.

Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators.

Circulation. 2003 Sep 30;108(13):1560-6. Epub 2003 Sep 15.PMID: 12975259 [PubMed - indexed for MEDLINE]Related articlesFree article

Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Amarenco P, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, O'Neill BJ, Rudolph AE, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators.

Atherosclerosis. 2009 Jun;204(2):515-20. Epub 2008 Sep 18.PMID: 18962621 [PubMed - indexed for MEDLINE]Related articles

Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.

Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A.

J Am Coll Cardiol. 2009 Aug 4;54(6):558-65. Epub 2009 Jul 2.PMID: 19643320 [PubMed - indexed for MEDLINE]Related articles